These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15529592)

  • 21. Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors.
    Galderisi M; de Divitiis O
    J Cardiovasc Pharmacol; 2008 Jun; 51(6):523-31. PubMed ID: 18520954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aldosterone, mineralocorticoid receptors and vascular inflammation.
    Funder JW
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):263-9. PubMed ID: 15134827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular benefits of aldosterone receptor antagonists.
    Williams GH
    Climacteric; 2003 Oct; 6 Suppl 3():29-35. PubMed ID: 15018246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aldosterone receptor antagonism and heart failure: insights from an outpatient clinic.
    Mariotti R; Borelli G; Coceani M; Zingaro S; Barison A; Morelli I; Rondinini L
    J Clin Pharm Ther; 2008 Aug; 33(4):349-56. PubMed ID: 18613852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The renin-angiotensin system].
    Hilgers KF
    Urologe A; 2009 Aug; 48(8):925-33; quiz 934-5. PubMed ID: 19669119
    [No Abstract]   [Full Text] [Related]  

  • 28. [Endocrinology of aldosterone].
    Ronconi V; Giacchetti G; Boscaro M
    Ital Heart J; 2005 May; 6 Suppl 1():5S-15S. PubMed ID: 15945295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP
    Cardiol Rev; 2006; 14(2):81-7. PubMed ID: 16493245
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aldosterone receptor antagonism in heart failure.
    Jennings DL; Kalus JS; O'Dell KM
    Pharmacotherapy; 2005 Aug; 25(8):1126-33. PubMed ID: 16207104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of the renin-angiotensin-aldosterone system in cardiovascular progenitor cell function.
    Qian C; Schoemaker RG; van Gilst WH; Roks AJ
    Clin Sci (Lond); 2009 Feb; 116(4):301-14. PubMed ID: 19138171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.
    Chrysostomou A; Pedagogos E; MacGregor L; Becker GJ
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):256-62. PubMed ID: 17699214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldosterone, mineralocorticoid receptors, and vascular inflammation.
    Fiebeler A; Muller DN; Shagdarsuren E; Luft FC
    Curr Opin Nephrol Hypertens; 2007 Mar; 16(2):134-42. PubMed ID: 17293689
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
    Sato A; Hayashi K; Saruta T
    Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hypertension in patients with diabetes].
    Poulsen PL; Hansen KW; Gaede PH; Rossing P
    Ugeskr Laeger; 2009 Jun; 171(24):2031-4. PubMed ID: 19523370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?
    Coca SG; Perazella MA
    Expert Rev Cardiovasc Ther; 2005 May; 3(3):497-512. PubMed ID: 15889977
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of disease: The role of aldosterone in kidney damage and clinical benefits of its blockade.
    Del Vecchio L; Procaccio M; Viganò S; Cusi D
    Nat Clin Pract Nephrol; 2007 Jan; 3(1):42-9. PubMed ID: 17183261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Old and new drugs to block aldosterone and ameliorate cardiovascular disease].
    Fiebeler A; Luft FC
    Dtsch Med Wochenschr; 2004 Nov; 129(46):2491-6. PubMed ID: 15536584
    [No Abstract]   [Full Text] [Related]  

  • 39. Mineralocorticoid resistance.
    Geller DS
    Clin Endocrinol (Oxf); 2005 May; 62(5):513-20. PubMed ID: 15853818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.
    Healey JS; Morillo CA; Connolly SJ
    Curr Opin Cardiol; 2005 Jan; 20(1):31-7. PubMed ID: 15596957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.